News

Show
news from

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors

Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting

Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

Anaveon appoints Dr Eduard Gasal as Chief Medical Officer

Load more

Search